Luliconazole, (+)- | CAS#256424-63-2

MedKoo Cat#: 527970 | Name: Luliconazole, (+)-

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Luliconazole, (+)- is a bioactive chemical.

Chemical Structure

Luliconazole, (+)-

CAS#256424-63-2 (S isomer)

Theoretical Analysis

MedKoo Cat#: 527970

Name: Luliconazole, (+)-

CAS#: 256424-63-2 (S isomer)

Chemical Formula: C14H9Cl2N3S2

Exact Mass: 352.9615

Molecular Weight: 354.27

Elemental Analysis: C, 47.47; H, 2.56; Cl, 20.01; N, 11.86; S, 18.10

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

187164-19-8 (R isomer) 256424-63-2 (S isomer) 101530-21-6

Synonym

Luliconazole, (+)-

IUPAC/Chemical Name

1H-Imidazole-1-acetonitrile, alpha-((4S)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene)-, (alphaE)-

InChi Key

YTAOBBFIOAEMLL-MNWMYKRDSA-N

InChi Code

InChI=1S/C14H9Cl2N3S2/c15-9-1-2-10(11(16)5-9)13-7-20-14(21-13)12(6-17)19-4-3-18-8-19/h1-5,8,13H,7H2/b14-12+/t13-/m1/s1

SMILES Code

N#C/C(N1C=CN=C1)=C2SC[C@H](C3=CC=C(Cl)C=C3Cl)S/2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 354.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Hagiwara S, Tamura T, Satoh K, Kamewada H, Nakano M, Shinden S, Yamaguchi H, Makimura K. The Molecular Identification and Antifungal Susceptibilities of Aspergillus Species Causing Otomycosis in Tochigi, Japan. Mycopathologia. 2018 Oct 5. doi: 10.1007/s11046-018-0299-9. [Epub ahead of print] PubMed PMID: 30291485. 2: Haghani I, Shams-Ghahfarokhi M, Dalimi Asl A, Shokohi T, Hedayati MT. Molecular identification and antifungal susceptibility of clinical fungal isolates from onychomycosis (uncommon and emerging species). Mycoses. 2018 Sep 25. doi: 10.1111/myc.12854. [Epub ahead of print] PubMed PMID: 30255665. 3: Omran SM, Taghizadeh-Armaki M, Zarrinfar H, Hedayati MT, Abastabar M, Moqarabzadeh V, Ansari S, Saber S, Hoseinnejad A, Miri A, Verweij PE, Seyedmousavi S. In-vitro antifungal susceptibility testing of lanoconazole and luliconazole against Aspergillus flavus as an important agent of invasive aspergillosis. J Infect Chemother. 2018 Sep 18. pii: S1341-321X(18)30239-3. doi: 10.1016/j.jiac.2018.07.018. [Epub ahead of print] PubMed PMID: 30241879. 4: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK500628/ PubMed PMID: 29999688. 5: Salehi Z, Shams-Ghahfarokhi M, Razzaghi-Abyaneh M. Antifungal drug susceptibility profile of clinically important dermatophytes and determination of point mutations in terbinafine-resistant isolates. Eur J Clin Microbiol Infect Dis. 2018 Oct;37(10):1841-1846. doi: 10.1007/s10096-018-3317-4. Epub 2018 Jul 7. PubMed PMID: 29980898. 6: Aslani N, Abastabar M, Hedayati MT, Shokohi T, Aghili SR, Diba K, Hosseini T, Bahrami B, Ebrahimpour A, Salehi M, Taheri Sarvtin M, Haghani I, Vafaei Moghaddam M. Molecular identification and antifungal susceptibility testing of Candida species isolated from dental plaques. J Mycol Med. 2018 Sep;28(3):433-436. doi: 10.1016/j.mycmed.2018.05.006. Epub 2018 May 24. PubMed PMID: 29805065. 7: Shokri A, Abastabar M, Keighobadi M, Emami S, Fakhar M, Teshnizi SH, Makimura K, Rezaei-Matehkolaei A, Mirzaei H. Promising antileishmanial activity of novel imidazole antifungal drug luliconazole against Leishmania major: In vitro and in silico studies. J Glob Antimicrob Resist. 2018 Sep;14:260-265. doi: 10.1016/j.jgar.2018.05.007. Epub 2018 May 21. PubMed PMID: 29793051. 8: Rudramurthy SM, Shankarnarayan SA, Dogra S, Shaw D, Mushtaq K, Paul RA, Narang T, Chakrabarti A. Mutation in the Squalene Epoxidase Gene of Trichophyton interdigitale and Trichophyton rubrum Associated with Allylamine Resistance. Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02522-17. doi: 10.1128/AAC.02522-17. Print 2018 May. PubMed PMID: 29530857; PubMed Central PMCID: PMC5923174. 9: Rezaei-Matehkolaei A, Khodavaisy S, Alshahni MM, Tamura T, Satoh K, Abastabar M, Shokoohi GR, Ahmadi B, Kord M, Taghipour S, Makimura K, Badali H. In Vitro Antifungal Activity of Novel Triazole Efinaconazole and Five Comparators against Dermatophyte Isolates. Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02423-17. doi: 10.1128/AAC.02423-17. Print 2018 May. PubMed PMID: 29530856; PubMed Central PMCID: PMC5923135. 10: Abastabar M, Al-Hatmi AMS, Vafaei Moghaddam M, de Hoog GS, Haghani I, Aghili SR, Shokohi T, Hedayati MT, Daie Ghazvini R, Kachuei R, Rezaei-Matehkolaei A, Makimura K, Meis JF, Badali H. Potent Activities of Luliconazole, Lanoconazole, and Eight Comparators against Molecularly Characterized Fusarium Species. Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e00009-18. doi: 10.1128/AAC.00009-18. Print 2018 May. PubMed PMID: 29530844; PubMed Central PMCID: PMC5923147. 11: Taghipour S, Kiasat N, Shafiei S, Halvaeezadeh M, Rezaei-Matehkolaei A, Zarei Mahmoudabadi A. Luliconazole, a new antifungal against Candida species isolated from different sources. J Mycol Med. 2018 Jun;28(2):374-378. doi: 10.1016/j.mycmed.2017.11.004. Epub 2017 Nov 29. PubMed PMID: 29198426. 12: Hasuko M, Shiomi R, Takahashi Y, Motoba K, Hirano H, Tsuboi R, Inagaki K. [Affinity of Luliconazole for Human Nail Derived Keratin]. Med Mycol J. 2017;58(4):J113-J119. doi: 10.3314/mmj.17-00009. Japanese. PubMed PMID: 29187718. 13: Shokoohi GR, Badali H, Mirhendi H, Ansari S, Rezaei-Matehkolaei A, Ahmadi B, Vaezi A, Alshahni MM, Makimura K. In Vitro Activities of Luliconazole, Lanoconazole, and Efinaconazole Compared with Those of Five Antifungal Drugs against Melanized Fungi and Relatives. Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e00635-17. doi: 10.1128/AAC.00635-17. Print 2017 Nov. PubMed PMID: 28848012; PubMed Central PMCID: PMC5655049. 14: Zargaran M, Taghipour S, Kiasat N, Aboualigalehdari E, Rezaei-Matehkolaei A, Zarei Mahmoudabadi A, Shamsizadeh F. Luliconazole, an alternative antifungal agent against Aspergillus terreus. J Mycol Med. 2017 Sep;27(3):351-356. doi: 10.1016/j.mycmed.2017.04.011. Epub 2017 May 5. PubMed PMID: 28483449. 15: Watanabe S, Kishida H, Okubo A. Efficacy and safety of luliconazole 5% nail solution for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study. J Dermatol. 2017 Jul;44(7):753-759. doi: 10.1111/1346-8138.13816. Epub 2017 Mar 23. PubMed PMID: 28332720. 16: Shimamura T, Miyamae A, Imai A, Hirayanagi K, Iwanaga T, Kubota N, Shibuya K. Comparison of Characteristics of Two Topical Therapeutic Agents for Onychomycosis. Med Mycol J. 2016;57(4):J141-J147. Japanese. PubMed PMID: 27904059. 17: Zhou BR, Lu Y, Permatasari F, Huang H, Li J, Liu J, Zhang JA, Luo D, Xu Y. The efficacy of fractional carbon dioxide (CO2) laser combined with luliconazole 1% cream for the treatment of onychomycosis: A randomized, controlled trial. Medicine (Baltimore). 2016 Nov;95(44):e5141. PubMed PMID: 27858846; PubMed Central PMCID: PMC5591094. 18: Abastabar M, Rahimi N, Meis JF, Aslani N, Khodavaisy S, Nabili M, Rezaei-Matehkolaei A, Makimura K, Badali H. Potent Activities of Novel Imidazoles Lanoconazole and Luliconazole against a Collection of Azole-Resistant and -Susceptible Aspergillus fumigatus Strains. Antimicrob Agents Chemother. 2016 Oct 21;60(11):6916-6919. doi: 10.1128/AAC.01193-16. Print 2016 Nov. PubMed PMID: 27572389; PubMed Central PMCID: PMC5075107. 19: Sarkar S, Sengupta D, Basak S, Damji SA, Shukla DK, Anurag D. Comparative assessment of the efficacy of topical ketoconazole and topical luliconazole in cases of pityriasis versicolor at a tertiary care hospital in eastern India: A prospective, open, randomized controlled trial. Indian Dermatol Online J. 2016 Jul-Aug;7(4):335-6. doi: 10.4103/2229-5178.185471. PubMed PMID: 27559523; PubMed Central PMCID: PMC4976428. 20: Rosen T. Tinea and Onychomycosis. Semin Cutan Med Surg. 2016 Jun;35(6 Suppl):S110-3. doi: 10.12788/j.sder.2016.035. PubMed PMID: 27537822.